Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis

References

• Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995;38: 151–60.
   Google Scholar
• Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. 2000;51:207–29.
   PubMed Web of Science ®Google Scholar
• Woo CH, Kim TH, Choi JA, Ryu HC, Lee JE, You HJ, et al. Inhibition of receptor internalization attenuates the TNF alpha-induced ROS generation in non-phagocytic cells. Biochem Bio-phys Res Commun. 2006;351:972–8.
   Google Scholar
• Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 2003;22:3898–909.
   PubMed Web of Science ®Google Scholar
• Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheu-matoid arthritis. Arthritis Rheum. 1998;41:1258–65.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol. 2001; 19:163-96.
   Google Scholar
• Pittoni V, Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, et al. Anti-tumor necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis. 2002;61:723–5.
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloprotein-ases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol. 2004;31:238–42.
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Takahashi M, Torikai E, Suzuki M, Ichikawa T, Nagafusa T, et al. Treatment with anti-TNF-alpha antibody inf-liximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:505–9.
   PubMed Web of Science ®Google Scholar
• Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1088–93.
   Google Scholar
• Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int. 2007;28:137–43.
   PubMed Web of Science ®Google Scholar
• Zoja C, Wang JM, Bettoni S, Sironi M, Renzi D, Chiaffarino F, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol. 1991;138:991–1003.
   PubMed Web of Science ®Google Scholar
• Visser CE, Tekstra J, Brouwer-Steenbergen JJ, Tuk CW, Boorsma DM, Sampat-Sardjoepersad SC, et al. Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin Exp Immunol. 1998;112: 270–5.
   Google Scholar
• Harigai M, Hara M, Yoshimura T, Leonard RI, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993;69:83–91.
   PubMedGoogle Scholar
• Guilloton F, Jean C, de Thonel A, Laurent G, Quillet-Mary A. Granzyme B induction signaling pathway in acute myeloid leukemia cell lines stimulated by tumor necrosis factor alpha and Fas ligand. Cell Signal. 2007;19:1132–40.
   Google Scholar
• Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int. 2008;28:245–51.
   Google Scholar
• Takahashi M, Ohishi T, Aoshima H, Kawana K, Kushida K, Inoue T, Horiuchi K. The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia. 1993;36:664–7.
   Google Scholar
• Catrina AT, Lampa J, Emestam S, Klint E, Bratt J, Klareskog L, et al. Anti-tumor necrosis factor (TNF)-alpha therapy (etaner-cept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford). 2002;41:484–9.
   PubMed Web of Science ®Google Scholar
• Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Sch-wartz CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry. 1988;27:4162–8.
   Google Scholar
• Huffnagle GB, Strieter RM, Standiford TJ, McDonald RA, Burdick MD, Kunkel SL, et al. The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J Immunol. 1995;155:4790–7.
   PubMedGoogle Scholar
• Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz 0, et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001;115: 554–62.
   Google Scholar
• Allavena P, Bianchi G, Zhou D, van Damme J, Jilek P, Sozzani S, et al. Induction of natural killer cell migration by monocyte che-motactic protein-1, -2 and -3. Eur J Immunol. 1994;24: 3233–6.
   Google Scholar
• Taub DD, Sayers TJ, Carter CR, Ortaldo JR. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol. 1995;155:3877–88.
   PubMed Web of Science ®Google Scholar
• Can MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattrac-tant. Proc Natl Acad Sci USA. 1994;91: 3652–6.
   Google Scholar
• Pulsatelli L, Dolzani P, Piacentini A, Silvestri T, Ruggeri R, Gualtieri G, et al. Chemokine production by human chondro-cytes. J Rheumatol. 1999;26:1992–2001.
   PubMed Web of Science ®Google Scholar
• Vogel CF, Nishimura N, Sciullo E, Wong P, Li W, Matsumura F. Modulation of the chemokines KC and MCP-1 by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) in mice. Arch Biochem Biophys. 2007;461:169–75.
   PubMed Web of Science ®Google Scholar
• Antoniades HN, Neville-Golden J, Galanopoulos T, Kradin RL, Valente AJ, Graves DT. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 1992;89:5371–80.
   PubMed Web of Science ®Google Scholar
• Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic oppor-tunities and controversies. Microcirculation. 2003;10:247–57.
   PubMed Web of Science ®Google Scholar
• Ellingsen T, Buus A, Stengaard-Pedersen K. Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J Rheumatol. 2001;28: 41–6.
   Google Scholar
• Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res. 2001;3:118–26.
   PubMedGoogle Scholar
• Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoat-tractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992;90:772–9.
   PubMed Web of Science ®Google Scholar
• Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994;93:921–8.
   Google Scholar
• Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol. 1997;182: 106–14.
   Google Scholar
• Gong JH, Ratkay LG, Waterfield JD, Lewis IC. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med. 1997;186:131–7.
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal anti-body in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2387–92.
   Google Scholar
• Yoo JK, Kwon H, Khil LY, Zhang L, Jun HS, Yoon JW. IL-18 Induces monocyte chemotactic protein-1 production in macro-phages through the phosphatidylinositol 3-kinase/Akt and MEK/ ERK1/2 pathways. J Immunol. 2005;175:8280–6.
   PubMed Web of Science ®Google Scholar
• Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood. 1997;90: 2804–9.
   Google Scholar
• Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Reg-ulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:529–33.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leuko-cyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43: 38–47.
   PubMed Web of Science ®Google Scholar
• Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–45.
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392:565–8.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie 0. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12: 121–7.
   Google Scholar
• Inoue T, Yamashita M, Higaki M. The new antirheumatic drug KE-298 suppresses monocyte chemoattractant protein (MCP)-1 and RANTES production in rats with adjuvant-induced arthritis and in IL-1-stimulated synoviocytes of patients with rheumatoid arthritis. Rheumatol Int. 2001;20: 149–53.
   Google Scholar
• Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett. 1997;57: 117–20.
   Google Scholar
• Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strider R, et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest. 1998;101:2910–9.
   PubMed Web of Science ®Google Scholar
• Boiardi L, Macchioni P, Meliconi R, Pulsatelli L, Facchini A, Salvarani C. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol. 1999;17:419–25.
   PubMed Web of Science ®Google Scholar
• Liu CC, Persechini PM, Young JD. PerforM and lymphocyte-mediated cytolysis. Immunol Rev. 1995;146:145–75.
   Google Scholar
• Ronday HK, van der Laan WH, Tak PP, de Roos JA, Bank RA, TeKoppele JM, et al. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology (Oxford). 2001;40:55–61.
   PubMed Web of Science ®Google Scholar
• Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE. The levels of soluble granzyme A and B are ele-vated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 1999;116:366–70.
   PubMed Web of Science ®Google Scholar